The LifeWatch MCT 1-Lead Patch is the newest addition to LifeWatch's cardiac diagnostic monitoring offering.
This latest clearance, combined with the recently obtained CE mark, enables LifeWatch to provide patients in many parts of the world with a new diagnostic monitoring patch alternative. The MCT 1-Lead Patch is capable of watching every heartbeat for adverse cardiac events and transmitting significant findings, in near real time, to a clinical service center for immediate follow-up, according to company executives. The MCT 1-Lead Patch technology is an easy-to-use, discrete and lightweight alternative to traditional recording and transmitting devices. It is significantly more comfortable for the patient and should therefore lead to an increase in the diagnostic yield as a result of improved patient compliance.
"I am very excited about this milestone which will now allow us to introduce our patch technology to a broader market. The FDA clearance represents yet another significant achievement for LifeWatch and further strengthens our position as an innovational leader in digital health," LifeWatch CEO Dr. Stephan Rietiker said.
Headquartered in Zug, Switzerland, LifeWatch AG is a healthcare technology and solutions company specializing in advanced digital health systems and wireless remote diagnostic patient monitoring services. LifeWatch AG has operative subsidiaries in the United States, Switzerland and Israel, and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services Inc. is a U.S.-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a developer and manufacturer of telemedicine products.